Natera (NASDAQ:NTRA) Reaches New 1-Year High at $133.00

Natera, Inc. (NASDAQ:NTRA) shares hit a new 52-week high on Tuesday . The company traded as high as $133.00 and last traded at $133.00, with a volume of 417 shares changing hands. The stock had previously closed at $129.67.

Analyst Ratings Changes

A number of brokerages have commented on NTRA. Piper Sandler restated an “overweight” rating and issued a $150.00 target price on shares of Natera in a research note on Friday, September 13th. BTIG Research raised their price objective on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Stephens reaffirmed an “overweight” rating and set a $125.00 target price on shares of Natera in a research report on Friday, August 9th. UBS Group dropped their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a research report on Friday, August 9th. Finally, Robert W. Baird raised their price target on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $120.07.

Natera Price Performance

The firm has a market capitalization of $15.61 billion, a P/E ratio of -40.74 and a beta of 1.53. The stock’s fifty day simple moving average is $113.80 and its 200 day simple moving average is $104.89. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. The firm had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. Natera’s revenue was up 58.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.97) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.96 EPS for the current year.

Insider Activity

In related news, CFO Michael Burkes Brophy sold 499 shares of the business’s stock in a transaction on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total transaction of $53,592.60. Following the transaction, the chief financial officer now directly owns 77,418 shares in the company, valued at approximately $8,314,693.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $108.87, for a total transaction of $293,949.00. Following the transaction, the insider now owns 301,808 shares in the company, valued at $32,857,836.96. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 499 shares of Natera stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $107.40, for a total transaction of $53,592.60. Following the completion of the sale, the chief financial officer now owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 86,197 shares of company stock worth $9,561,358. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sanctuary Advisors LLC purchased a new stake in shares of Natera during the second quarter valued at $380,000. Gordian Capital Singapore Pte Ltd acquired a new stake in Natera during the 2nd quarter worth about $285,000. Maven Securities LTD purchased a new stake in Natera during the 2nd quarter valued at about $217,000. HWG Holdings LP purchased a new stake in Natera during the 2nd quarter valued at about $326,000. Finally, Quarry LP increased its holdings in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.